In the BioHarmony Drug Report Database
Emgality (galcanezumab) is an antibody pharmaceutical. Galcanezumab was first approved as Emgality on 2018-09-27. It is used to treat cluster headache in the USA. It has been approved in Europe to treat migraine disorders. The pharmaceutical is active against calcitonin; calcitonin gene-related peptide 1. In addition, it is known to target calcitonin gene-related peptide 1.
Image (chem structure or protein)